KR101874557B1 - 시토크롬 p450 모노옥시게나아제 억제제의 제조 방법 및 관련 중간체 - Google Patents

시토크롬 p450 모노옥시게나아제 억제제의 제조 방법 및 관련 중간체 Download PDF

Info

Publication number
KR101874557B1
KR101874557B1 KR1020177009970A KR20177009970A KR101874557B1 KR 101874557 B1 KR101874557 B1 KR 101874557B1 KR 1020177009970 A KR1020177009970 A KR 1020177009970A KR 20177009970 A KR20177009970 A KR 20177009970A KR 101874557 B1 KR101874557 B1 KR 101874557B1
Authority
KR
South Korea
Prior art keywords
formula
compound
salt
reaction
dichloromethane
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020177009970A
Other languages
English (en)
Korean (ko)
Other versions
KR20170043672A (ko
Inventor
리차드 폴니아섹
스티븐 파이퍼
리차드 유
아론 쿨렌
에릭 다우디
즈엉 쩐
케네스 켄트
종신 저우
더그 코르도
레아 이스턴
Original Assignee
길리애드 사이언시즈, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42634770&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101874557(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 길리애드 사이언시즈, 인코포레이티드 filed Critical 길리애드 사이언시즈, 인코포레이티드
Publication of KR20170043672A publication Critical patent/KR20170043672A/ko
Application granted granted Critical
Publication of KR101874557B1 publication Critical patent/KR101874557B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/30Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C209/00Preparation of compounds containing amino groups bound to a carbon skeleton
    • C07C209/62Preparation of compounds containing amino groups bound to a carbon skeleton by cleaving carbon-to-nitrogen, sulfur-to-nitrogen, or phosphorus-to-nitrogen bonds, e.g. hydrolysis of amides, N-dealkylation of amines or quaternary ammonium compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C209/00Preparation of compounds containing amino groups bound to a carbon skeleton
    • C07C209/68Preparation of compounds containing amino groups bound to a carbon skeleton from amines, by reactions not involving amino groups, e.g. reduction of unsaturated amines, aromatisation, or substitution of the carbon skeleton
    • C07C209/70Preparation of compounds containing amino groups bound to a carbon skeleton from amines, by reactions not involving amino groups, e.g. reduction of unsaturated amines, aromatisation, or substitution of the carbon skeleton by reduction of unsaturated amines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C303/00Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
    • C07C303/34Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of amides of sulfuric acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C307/00Amides of sulfuric acids, i.e. compounds having singly-bound oxygen atoms of sulfate groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C307/02Monoamides of sulfuric acids or esters thereof, e.g. sulfamic acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C307/00Amides of sulfuric acids, i.e. compounds having singly-bound oxygen atoms of sulfate groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C307/04Diamides of sulfuric acids
    • C07C307/06Diamides of sulfuric acids having nitrogen atoms of the sulfamide groups bound to acyclic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/28Radicals substituted by nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020177009970A 2009-04-03 2010-04-01 시토크롬 p450 모노옥시게나아제 억제제의 제조 방법 및 관련 중간체 Active KR101874557B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16649809P 2009-04-03 2009-04-03
US61/166,498 2009-04-03
PCT/US2010/029633 WO2010115000A2 (en) 2009-04-03 2010-04-01 Methods and intermediates for preparing pharmaceutical agents

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020117026120A Division KR101728375B1 (ko) 2009-04-03 2010-04-01 시토크롬 p450 모노옥시게나아제 억제제의 제조 방법 및 관련 중간체

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020187018487A Division KR20180077324A (ko) 2009-04-03 2010-04-01 시토크롬 p450 모노옥시게나아제 억제제의 제조 방법 및 관련 중간체

Publications (2)

Publication Number Publication Date
KR20170043672A KR20170043672A (ko) 2017-04-21
KR101874557B1 true KR101874557B1 (ko) 2018-07-04

Family

ID=42634770

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020117026120A Active KR101728375B1 (ko) 2009-04-03 2010-04-01 시토크롬 p450 모노옥시게나아제 억제제의 제조 방법 및 관련 중간체
KR1020187018487A Ceased KR20180077324A (ko) 2009-04-03 2010-04-01 시토크롬 p450 모노옥시게나아제 억제제의 제조 방법 및 관련 중간체
KR1020177009970A Active KR101874557B1 (ko) 2009-04-03 2010-04-01 시토크롬 p450 모노옥시게나아제 억제제의 제조 방법 및 관련 중간체

Family Applications Before (2)

Application Number Title Priority Date Filing Date
KR1020117026120A Active KR101728375B1 (ko) 2009-04-03 2010-04-01 시토크롬 p450 모노옥시게나아제 억제제의 제조 방법 및 관련 중간체
KR1020187018487A Ceased KR20180077324A (ko) 2009-04-03 2010-04-01 시토크롬 p450 모노옥시게나아제 억제제의 제조 방법 및 관련 중간체

Country Status (27)

Country Link
US (4) US8497396B2 (enExample)
EP (2) EP2414325B1 (enExample)
JP (8) JP5612662B2 (enExample)
KR (3) KR101728375B1 (enExample)
CN (4) CN111217808A (enExample)
AP (1) AP2887A (enExample)
AR (1) AR076027A1 (enExample)
AU (1) AU2010232559B2 (enExample)
BR (1) BRPI1012638B8 (enExample)
CA (4) CA2754698C (enExample)
CL (1) CL2011002370A1 (enExample)
CO (1) CO6400216A2 (enExample)
EA (2) EA201590979A1 (enExample)
EC (1) ECSP11011391A (enExample)
ES (1) ES2548252T3 (enExample)
HK (1) HK1223912A1 (enExample)
IL (4) IL215399A (enExample)
MX (2) MX338731B (enExample)
NZ (4) NZ617773A (enExample)
PE (1) PE20120617A1 (enExample)
PT (1) PT2414325E (enExample)
SG (2) SG10201404926UA (enExample)
TW (2) TWI464165B (enExample)
UA (1) UA108738C2 (enExample)
UY (1) UY32535A (enExample)
WO (1) WO2010115000A2 (enExample)
ZA (1) ZA201107430B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA108738C2 (uk) 2009-04-03 2015-06-10 Спосіб одержання інгібітора цитохром р450 монооксигенази та залучені проміжні сполуки
JP2012140390A (ja) * 2011-01-06 2012-07-26 Sumitomo Chemical Co Ltd α−アミノ−γ−ブチロラクトンの製造方法
JP2014513123A (ja) * 2011-05-02 2014-05-29 ギリアード サイエンシーズ, インコーポレイテッド 無定形固体の塩
HK1205095A1 (en) 2012-02-03 2015-12-11 Gilead Sciences, Inc. Methods and intermediates for preparing pharmaceutical agents
WO2014047849A1 (zh) * 2012-09-27 2014-04-03 上海迪赛诺化学制药有限公司 细胞色素p450单加氧酶抑制剂中间体及其制法和用途
CN103694196A (zh) * 2012-09-27 2014-04-02 上海迪赛诺化学制药有限公司 细胞色素p450单加氧酶抑制剂中间体及其制法和用途
WO2014057498A2 (en) 2012-10-08 2014-04-17 Mylan Laboratories Ltd. Process for the preparation of cobicistat intermediates
EP2938603A1 (en) * 2012-12-26 2015-11-04 Assia Chemical Industries Ltd. Cobicostat dichlohydrate salt
CN104370777A (zh) * 2013-08-13 2015-02-25 上海迪赛诺化学制药有限公司 合成(2r,5r)-1,6-二苯基己烷-2,5-二胺及其盐的中间体及所述中间体的制备方法和应用
WO2015079415A1 (en) * 2013-11-29 2015-06-04 Mylan Laboratories Ltd. Amorphous cobicistat solid dispersion
US9975864B2 (en) 2013-12-03 2018-05-22 Mylan Laboratories Limited Preparation of cobicistat intermediates
CN104193643B (zh) * 2014-09-12 2016-02-10 宁波九胜创新医药科技有限公司 用于合成抗艾滋病药物增强剂cobicistat的中间体
CN104447472A (zh) * 2014-11-06 2015-03-25 江苏森萱医药化工股份有限公司 D)-2-苄基-n,n-二甲基氮杂环丙烷基-1-磺酰胺合成方法
CN104557565B (zh) * 2015-01-08 2016-07-06 浙江工业大学 抗艾滋病药物增强剂Cobicistat关键中间体盐酸盐的制备方法
US10454867B2 (en) * 2015-02-09 2019-10-22 Airwatch Llc Enhanced e-mail delivery to mobile devices
EP3259267A4 (en) * 2015-02-18 2019-01-23 MSN Laboratories Private Limited A NOVEL PROCESS FOR THE PREPARATION OF 1,3-THIAZOL-5-YLMETHYL [(2R, 5R) -5 - {[(2S) -2 - [(METHYL {[2- (PROPAN-2-YL) -1) CARBAMATE 3-thiazol-4-yl] methyl} carbamoyl) amino] -4- (morpholin-4-yl) butanoyl] amino} -1,6-DIPHÉNYLHEXAN-2-YL]
CN107674039A (zh) * 2016-08-01 2018-02-09 上海朴颐化学科技有限公司 一种可比西他中间体的制备方法
EP3518935A1 (en) 2016-09-27 2019-08-07 Gilead Sciences, Inc. Therapeutic compositions for treatment of human immunodeficiency virus
CN109912530A (zh) * 2017-12-13 2019-06-21 上海奥博生物医药技术有限公司 一种可比司他原料杂质的制备方法
CN109232301B (zh) * 2018-10-15 2021-01-01 天津希恩思生化科技有限公司 一种四异丙基肼的制备方法
CN110642721B (zh) * 2018-12-21 2022-09-30 安徽贝克生物制药有限公司 盐酸司来吉兰的制备方法
CN110878071A (zh) * 2019-11-21 2020-03-13 华南农业大学 一种α-氨基-γ-丁内酯及其盐的制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008010921A2 (en) * 2006-07-07 2008-01-24 Gilead Sciences, Inc. Modulators of pharmacokinetic properties of therapeutics
WO2008103949A1 (en) * 2007-02-23 2008-08-28 Gilead Sciences, Inc. Modulators of pharmacokinetic properties of therapeutics

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU778198B2 (en) * 1999-06-04 2004-11-25 Abbvie Inc. Improved pharmaceutical formulations
US20030153771A1 (en) 2001-09-27 2003-08-14 Kolb Hartmuth C. Large scale synthesis of optically pure aziridines
AU2003232173A1 (en) * 2002-06-12 2003-12-31 Qsi Pharma A/S Compounds and methods for controlling bacterial virulence
MX2007000884A (es) * 2004-07-23 2007-03-12 Procter & Gamble Composicion detergente liquida para una limpieza mejorada de la grasa y de la suciedad del almidon a baja temperatura.
US7786153B2 (en) * 2005-03-02 2010-08-31 Abbott Laboratories Inc. Compounds that are useful for improving pharmacokinetics
TWI448457B (zh) * 2007-07-06 2014-08-11 Gilead Sciences Inc 治療劑的藥物動力學性質之調節劑
JP5629585B2 (ja) * 2008-01-04 2014-11-19 ギリアード サイエンシーズ, インコーポレイテッド シトクロムp450のインヒビター
MX342377B (es) 2008-05-02 2016-09-27 Gilead Sciences Inc Uso de particulas trasportadoras solidas para mejorar la capacidad de procesamiento de un agente farmaceutico.
UA108738C2 (uk) 2009-04-03 2015-06-10 Спосіб одержання інгібітора цитохром р450 монооксигенази та залучені проміжні сполуки

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008010921A2 (en) * 2006-07-07 2008-01-24 Gilead Sciences, Inc. Modulators of pharmacokinetic properties of therapeutics
WO2008103949A1 (en) * 2007-02-23 2008-08-28 Gilead Sciences, Inc. Modulators of pharmacokinetic properties of therapeutics

Also Published As

Publication number Publication date
HK1214265A1 (zh) 2016-07-22
CA2925137C (en) 2018-07-31
JP2014193897A (ja) 2014-10-09
JP2012522797A (ja) 2012-09-27
CN104876888B (zh) 2018-06-15
EA201590979A1 (ru) 2016-02-29
TW201518283A (zh) 2015-05-16
CN107382997A (zh) 2017-11-24
EP3009434A1 (en) 2016-04-20
JP2023002679A (ja) 2023-01-10
IL250068A0 (en) 2017-03-30
AU2010232559B2 (en) 2015-06-18
MX2011010397A (es) 2011-10-24
JP6336161B2 (ja) 2018-06-06
IL237643A0 (en) 2015-04-30
CA2754698C (en) 2016-06-07
CN111217808A (zh) 2020-06-02
NZ594864A (en) 2014-03-28
ZA201107430B (en) 2012-12-27
WO2010115000A3 (en) 2011-09-22
US9428473B2 (en) 2016-08-30
JP2018162274A (ja) 2018-10-18
MX338731B (es) 2016-04-28
ES2548252T3 (es) 2015-10-15
JP2020189861A (ja) 2020-11-26
CA2754698A1 (en) 2010-10-07
BRPI1012638A2 (pt) 2016-04-05
CA3008903A1 (en) 2010-10-07
US9115100B2 (en) 2015-08-25
CN102438982A (zh) 2012-05-02
KR20180077324A (ko) 2018-07-06
JP6180561B2 (ja) 2017-08-16
IL237642A (en) 2017-01-31
SG174585A1 (en) 2011-10-28
WO2010115000A2 (en) 2010-10-07
HK1223912A1 (en) 2017-08-11
CN107382997B (zh) 2021-02-26
TWI464165B (zh) 2014-12-11
CA3083433A1 (en) 2010-10-07
AP2887A (en) 2014-05-31
PE20120617A1 (es) 2012-05-26
US8497396B2 (en) 2013-07-30
UY32535A (es) 2010-10-29
ECSP11011391A (es) 2012-03-30
CA3083433C (en) 2022-08-09
EA201190179A1 (ru) 2013-01-30
JP2016128476A (ja) 2016-07-14
JP5612662B2 (ja) 2014-10-22
JP2017122107A (ja) 2017-07-13
AR076027A1 (es) 2011-05-11
CA3008903C (en) 2021-06-08
HK1166976A1 (zh) 2012-11-16
US20100256366A1 (en) 2010-10-07
US20160002186A1 (en) 2016-01-07
JP5986599B2 (ja) 2016-09-06
CN104876888A (zh) 2015-09-02
EP2414325B1 (en) 2015-08-26
US20140088304A1 (en) 2014-03-27
KR101728375B1 (ko) 2017-04-19
NZ708978A (en) 2017-01-27
CL2011002370A1 (es) 2012-05-25
SG10201404926UA (en) 2015-02-27
NZ726536A (en) 2018-04-27
KR20120006035A (ko) 2012-01-17
IL237643A (en) 2017-01-31
IL237642A0 (en) 2015-04-30
BRPI1012638B8 (pt) 2021-05-25
KR20170043672A (ko) 2017-04-21
UA108738C2 (uk) 2015-06-10
IL215399A (en) 2015-11-30
CO6400216A2 (es) 2012-03-15
PT2414325E (pt) 2015-10-29
CN102438982B (zh) 2015-05-06
AP2011005864A0 (en) 2011-10-31
JP2018008983A (ja) 2018-01-18
IL215399A0 (en) 2011-12-29
AU2010232559A1 (en) 2011-10-06
AU2010232559A8 (en) 2011-11-10
BRPI1012638B1 (pt) 2021-04-20
EA022739B1 (ru) 2016-02-29
NZ617773A (en) 2016-02-26
EP2414325A2 (en) 2012-02-08
CA2925137A1 (en) 2010-10-07
US20150005493A1 (en) 2015-01-01
US8853210B2 (en) 2014-10-07
JP6491706B2 (ja) 2019-03-27
HK1245785A1 (zh) 2018-08-31
TW201100412A (en) 2011-01-01

Similar Documents

Publication Publication Date Title
KR101874557B1 (ko) 시토크롬 p450 모노옥시게나아제 억제제의 제조 방법 및 관련 중간체
HK1166976B (en) Method of preparing an inhibitor of cytochrome p450 monooxygenase, and intermediates involved
HK40022057A (en) Method and intermediates for preparing pharmaceutical agents
HK1245785B (zh) 用於制备药物药剂的方法和中间体

Legal Events

Date Code Title Description
A107 Divisional application of patent
A201 Request for examination
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20170412

Application number text: 1020117026120

Filing date: 20111102

PA0201 Request for examination
PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20170504

Patent event code: PE09021S01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20171123

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20180327

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20180628

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20180629

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20210527

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20220517

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20230518

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20240522

Start annual number: 7

End annual number: 7